INmune Bio Target of Unusually Large Options Trading (NASDAQ:INMB)

INmune Bio, Inc. (NASDAQ:INMBGet Free Report) was the recipient of some unusual options trading activity on Friday. Traders bought 3,375 put options on the stock. This represents an increase of approximately 101% compared to the typical daily volume of 1,681 put options.

Hedge Funds Weigh In On INmune Bio

A number of hedge funds have recently added to or reduced their stakes in INMB. Quarry LP bought a new stake in shares of INmune Bio during the first quarter valued at about $48,000. Wells Fargo & Company MN increased its stake in INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after purchasing an additional 2,155 shares in the last quarter. Beacon Pointe Advisors LLC purchased a new position in INmune Bio in the 4th quarter worth about $48,000. JPMorgan Chase & Co. grew its stake in INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock valued at $53,000 after acquiring an additional 5,461 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC purchased a new position in INmune Bio during the 1st quarter valued at about $91,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Stock Down 11.9%

INMB opened at $6.38 on Friday. The firm has a market capitalization of $146.61 million, a P/E ratio of -3.31 and a beta of 1.55. The firm’s 50 day moving average is $7.52 and its 200-day moving average is $7.28. INmune Bio has a 52-week low of $4.32 and a 52-week high of $10.50.

INmune Bio (NASDAQ:INMBGet Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.43). The company had revenue of $0.05 million for the quarter. Equities analysts expect that INmune Bio will post -2.24 earnings per share for the current fiscal year.

About INmune Bio

(Get Free Report)

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

Read More

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.